GSC 53

Drug Profile

GSC 53

Latest Information Update: 05 Jun 2002

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics
  • Class Glycoconjugates; Trisaccharides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypersensitivity; Transplant rejection

Most Recent Events

  • 05 Jun 2002 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 05 Jun 2002 Discontinued - Preclinical for Allergy in USA (unspecified route)
  • 30 May 2001 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top